Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD5658 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 6 - 8 cohorts | EXPERIMENTAL | 6 patients in each cohort will receive AZD5658 |
| Name | Type | Description |
|---|---|---|
| AZD5658 | DRUG | oral suspension, escalating single doses |
| Placebo | DRUG | oral suspension,single doses |
Inclusion Criteria: * Patients must be of non-childbearing potential. * Body mass index between greater than or equal to 19 and less than or equal to 40 kg/m2 * Patients with confirmed Type 2 Diabetes diagnosis for at least 1 year and treated with Metformin Exclusion Criteria: * Clinically signif...
Top 20 of 31 competitors
AZD5658 is an investigational small molecule being developed for the treatment of Type 2 Diabetes. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied to assess its safety, tolerability, and effects in patients with this condition.
AZD5658 is being developed by AstraZeneca PLC, a biopharmaceutical company traded on the stock exchange under the ticker symbol AZN. The company is conducting clinical research on this investigational drug for the treatment of Type 2 Diabetes.
AZD5658 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and tolerability. The drug is being studied for the treatment of Type 2 Diabetes.
AZD5658 has been studied in one completed Phase 1 clinical trial with the identifier NCT01176097. This trial assessed the safety, tolerability, pharmacokinetics, pharmacodynamics, and the effect of fasting after single oral doses of AZD5658 in patients with Type 2 Diabetes. The trial enrolled 24 participants and was conducted in the United States.
AZD5658 is the primary name for this investigational drug. No alternative names have been established for this compound in the available clinical trial information. It is being developed by AstraZeneca PLC for the treatment of Type 2 Diabetes.